Hui Zhan1, Jian-Ying Ma1, Qi-Chao Jian2. 1. Department of Dermatology, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, No. 141, Tianjin Road, Huangshi, Hubei, China. 2. Department of Dermatology, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, No. 141, Tianjin Road, Huangshi, Hubei, China. Electronic address: jianqc999@163.com.
Abstract
INTRODUCTION: Recently, the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) has been widely evaluated in many cancers. Here we assessed the prognostic value of pretreatment NLR in melanoma. METHODS: A range of online databases was systematically searched up to March,2018 for identify available studies which assessed the prognostic significance of NLR. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) were weighted by generic inverse-variance and pooled in random effects meta-analysis. RESULTS: Twelve studies with 4593 individuals were included. Patients with elevated NLR had a significantly shorter overall survival (OS) (HR: 1.56, 95% CI: 1.28-1.90, p < .001) and disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.86; 95% CI = 1.24-2.80; P = .003). Subgroup analyses showed that the negative prognostic effect of elevated NLR on OS remained substantial in North American and Europen populations and patients with non-metastatic and metastatic stage. Additionally, elevated NLR was related to worse OS in patients with melanoma, regardless of the sample size and the cut-off value. CONCLUSION: Our findings suggest that elevated pretreatment NLR was associated with poor prognosis in melanoma patients, suggesting NLR might be a prognostic factor in patients with melanoma.
INTRODUCTION: Recently, the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) has been widely evaluated in many cancers. Here we assessed the prognostic value of pretreatment NLR in melanoma. METHODS: A range of online databases was systematically searched up to March,2018 for identify available studies which assessed the prognostic significance of NLR. Data from studies reporting a hazard ratio (HR) and 95% confidence interval (CI) were weighted by generic inverse-variance and pooled in random effects meta-analysis. RESULTS: Twelve studies with 4593 individuals were included. Patients with elevated NLR had a significantly shorter overall survival (OS) (HR: 1.56, 95% CI: 1.28-1.90, p < .001) and disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.86; 95% CI = 1.24-2.80; P = .003). Subgroup analyses showed that the negative prognostic effect of elevated NLR on OS remained substantial in North American and Europen populations and patients with non-metastatic and metastatic stage. Additionally, elevated NLR was related to worse OS in patients with melanoma, regardless of the sample size and the cut-off value. CONCLUSION: Our findings suggest that elevated pretreatment NLR was associated with poor prognosis in melanomapatients, suggesting NLR might be a prognostic factor in patients with melanoma.
Authors: Denise Bernhardt; Sophie Aufderstrasse; Laila König; Sebastian Adeberg; Farastuk Bozorgmehr; Petros Christopoulos; Rami A El Shafie; Juliane Hörner-Rieber; Jutta Kappes; Michael Thomas; Felix Herth; Martin Steins; Jürgen Debus; Stefan Rieken Journal: Cancer Manag Res Date: 2018-11-30 Impact factor: 3.989
Authors: Lucas José Caram; Francisco Calderon; Esteban Masino; Victoria Ardiles; Ezequiel Mauro; Leila Haddad; Juan Pekolj; Jimena Vicens; Adrian Gadano; Eduardo de Santibañes; Martín de Santibañes Journal: Ann Hepatobiliary Pancreat Surg Date: 2022-02-28
Authors: Tal Grenader; Marianne E Pavel; Philippe B Ruszniewski; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Xuan-Mai Truong Thanh; Martyn E Caplin Journal: Anticancer Drugs Date: 2020-03 Impact factor: 2.389
Authors: Alyss V Robinson; Claire Keeble; Michelle C I Lo; Owen Thornton; Howard Peach; Marc D S Moncrieff; Donald J Dewar; Ryckie G Wade Journal: Cancer Immunol Immunother Date: 2020-01-23 Impact factor: 6.968